MENU
+Compare
NBIX
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$124.39
Change
-$0.62 (-0.50%)
Capitalization
13.72B

NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States... Show more

Industry: #Biotechnology
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NBIX with price predictions
Jun 13, 2025

NBIX in +2.37% Uptrend, growing for three consecutive days on May 28, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 22, 2025. You may want to consider a long position or call options on NBIX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 253 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on May 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where NBIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on May 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (62.115). P/E Ratio (57.202) is within average values for comparable stocks, (88.968). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (19.096).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NBIX is expected to report earnings to rise 39.77% to 97 cents per share on August 05

Neurocrine Biosciences NBIX Stock Earnings Reports
Q2'25
Est.
$0.98
Q1'25
Missed
by $0.07
Q4'24
Beat
by $0.12
Q3'24
Beat
by $0.29
Q2'24
Beat
by $0.50
The last earnings report on May 05 showed earnings per share of 69 cents, missing the estimate of 76 cents. With 775.18K shares outstanding, the current market capitalization sits at 13.72B.
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
1400
Web
https://www.neurocrine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FTS48.160.17
+0.35%
Fortis
GLDD11.47-0.17
-1.46%
Great Lakes Dredge & Dock Corp
BHF57.04-1.11
-1.91%
Brighthouse Financial
UOKA2.48-0.07
-2.92%
MDJM Ltd
NA10.39-0.51
-4.68%
Nano Labs Ltd

NBIX and Stocks

Correlation & Price change

A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.50%
LFCR - NBIX
31%
Poorly correlated
-1.46%
EOLS - NBIX
29%
Poorly correlated
-2.46%
CGC - NBIX
29%
Poorly correlated
-3.27%
ELAN - NBIX
28%
Poorly correlated
-2.54%
TLRY - NBIX
26%
Poorly correlated
-2.95%
More